Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 31, Number 1—January 2025
Dispatch

Case Reports of Human Monkeypox Virus Infections, Uganda, 2024

Nicholas Bbosa, Stella E. Nabirye, Hamidah S. Namagembe, Ronald Kiiza, Alfred Ssekagiri, Mary Munyagwa, Arafat Bwambale, Stephen Bagonza, Henry Kyobe Bosa, Robert Downing, Julius Lutwama, Pontiano Kaleebu, and Deogratius SsemwangaComments to Author 
Author affiliation: Uganda Virus Research Institute, Entebbe, Uganda (N. Bbosa, S.E. Nabirye, A. Ssekagiri, R. Downing, J. Lutwama, P. Kaleebu, D. Ssemwanga); Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe (N. Bbosa, H.S. Namagembe, R. Kiiza, P. Kaleebu, D. Ssemwanga); Bwera General Hospital, Bwera, Uganda (M. Munyagwa); Kasese District Local Government, Kasese, Uganda (A. Bwambale, S. Bagonza); Ministry of Health of Uganda, Kampala, Uganda (H.K. Bosa); Uganda Peoples’ Defence Forces, Kampala (H.K. Bosa); Makerere University Lung Institute, Kampala (H.K. Bosa)

Main Article

Table

Summary of PCR and genotyping results in study of human MPXV infections, Uganda, 2024*

Case no. Age/sex Sample type Date of sample reception at the laboratory Date of qPCR PCR mpox
Date of NGS UVRI Metagenomics Dragen Microbial Enrichment Plus
Roche Creative Biogene
1 37 y/F Blood 2024 Jul 20 2024 Jul 21 ND ND ND ND
Swab 2024 Jul 20 2024 Jul 21 Positive (Ct 18.29) Positive (Ct 21.18) 2024 Jul 22 MPXV MPXV
2 22 y/F Blood 2024 Jul 20 2024 Jul 21 ND ND ND ND ND
Swab 2024 Jul 20 2024 Jul 21 Positive (Ct 35.4) Negative 2024 Jul 22 MPXV MPXV
3 1 y/F Blood 2024 Jul 20 2024 Jul 21 ND ND ND ND ND
Swab 2024 Jul 20 2024 Jul 21 Negative Negative ND ND ND
4 11 mo/M Swab 2024 Jul 20 2024 Jul 21 Negative Negative ND ND ND
5 35 y/F Swab 2024 Jul 20 2024 Jul 21 Negative Negative ND ND ND
6 Unknown/F Swab 2024 Jul 20 2024 Jul 21 Negative Negative ND ND ND

*Case definitions: Clinical criteria for a suspected case are new characteristic rash on the skin, ano-genital or elsewhere on the body, which may include single or multiple lesions or meets one of the epidemiologic criteria and has a high clinical suspicion for mpox. Criteria for probably case: no suspicion of other recent Orthopoxvirus exposure and demonstration of the presence of Orthopoxvirus DNA by PCR of a clinical specimen. Laboratory criteria: detection of MPXV-specific DNA sequences by PCR and /or sequencing of a clinical specimen. Epidemiologic criteria: >1 of the following epidemiologic links in the last 21 d before symptom onset: reports having contact with a person or persons with a similar appearing rash or who received a diagnosis of confirmed or probable mpox or traveled outside Uganda to a country with confirmed cases of mpox or where MPXV is endemic like the Democratic Republic of Congo or had close or intimate in-person contact with persons in a social network currently experiencing MPXV activity. Ct, cycle threshold; MPXV, monkeypox virus; NGS, next-generation sequencing; ND, not done; qPCR, quantitative PCR.

Main Article

Page created: November 11, 2024
Page updated: December 22, 2024
Page reviewed: December 22, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external